Literature DB >> 28760741

Application of the 2014 NICE cholesterol guidelines in the English population: a cross-sectional analysis.

Peter Ueda1, Thomas Wai-Chun Lung2, Philip Clarke3, Goodarz Danaei4.   

Abstract

BACKGROUND: The 2014 guidelines on cardiovascular risk assessment and lipid modification from the National Institute for Health and Care Excellence (NICE) recommend statin therapy for adults with prevalent cardiovascular disease (CVD), and for adults with a 10-year CVD risk of ≥10%, estimated using the QRISK2 algorithm. AIM: To determine risk factor levels required to exceed the risk threshold for statin therapy, and to estimate the number of adults in England who would require statin therapy under the guidelines. DESIGN AND
SETTING: Cross-sectional study using a sample representative of the English population aged 30-84 years.
METHOD: To estimate 10-year CVD risk different combinations of risk factor levels were entered into the QRISK2 algorithm. The NICE guidelines were applied to the sample using data from the Health Survey for England 2011.
RESULTS: Even with optimal risk factor levels, males of different ethnicities would exceed the 10% risk threshold between the ages of 60 and 70 years, and females would exceed the threshold between 65 and 75 years. Under the NICE guidelines, 11.8 million males and females (37% of the adults aged 30-84 years) would require statin therapy, most of them (9.8 million) for primary prevention. When analysed by age, 95% of males and 66% of females without CVD in ages 60-74 years, including all males and females in ages 75-84 years, would require statin therapy.
CONCLUSION: Under the 2014 NICE guidelines, 11.8 million (37%) adults in England aged 30-84 years, including almost all males >60 years in all females >75 years, require statin therapy. © British Journal of General Practice 2017.

Entities:  

Keywords:  HMG-CoA reductase inhibitors; cardiovascular disease; general practice; prevention; risk; statins

Mesh:

Substances:

Year:  2017        PMID: 28760741      PMCID: PMC5569739          DOI: 10.3399/bjgp17X692141

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  17 in total

1.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson
Journal:  J Am Coll Cardiol       Date:  2013-11-12       Impact factor: 24.094

2.  Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.

Authors:  Ankur Pandya; Stephen Sy; Sylvia Cho; Milton C Weinstein; Thomas A Gaziano
Journal:  JAMA       Date:  2015-07-14       Impact factor: 56.272

3.  Statins for millions more?

Authors: 
Journal:  Lancet       Date:  2014-02-22       Impact factor: 79.321

4.  'Should we reconsider the role of age in treatment allocation for primary prevention of cardiovascular disease?' No, but we can improve risk communication metrics.

Authors:  Rod Jackson; Andrew Kerr; Sue Wells
Journal:  Eur Heart J       Date:  2017-05-21       Impact factor: 29.983

5.  Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2.

Authors:  Julia Hippisley-Cox; Carol Coupland; Yana Vinogradova; John Robson; Rubin Minhas; Aziz Sheikh; Peter Brindle
Journal:  BMJ       Date:  2008-06-23

Review 6.  Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3).

Authors: 
Journal:  Heart       Date:  2014-04       Impact factor: 5.994

7.  Mass treatment with statins.

Authors:  Ben Goldacre; Liam Smeeth
Journal:  BMJ       Date:  2014-07-22

8.  Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies.

Authors:  David Wormser; Stephen Kaptoge; Emanuele Di Angelantonio; Angela M Wood; Lisa Pennells; Alex Thompson; Nadeem Sarwar; Jorge R Kizer; Debbie A Lawlor; Børge G Nordestgaard; Paul Ridker; Veikko Salomaa; June Stevens; Mark Woodward; Naveed Sattar; Rory Collins; Simon G Thompson; Gary Whitlock; John Danesh
Journal:  Lancet       Date:  2011-03-26       Impact factor: 79.321

Review 9.  Statins for primary cardiovascular prevention in the elderly.

Authors:  Juan Pedro-Botet; Elisenda Climent; Juan J Chillarón; Rocio Toro; David Benaiges; Juana A Flores-Le Roux
Journal:  J Geriatr Cardiol       Date:  2015-07       Impact factor: 3.327

Review 10.  Systematic review of clinical practice guidelines recommendations about primary cardiovascular disease prevention for older adults.

Authors:  Jesse Jansen; Shannon McKinn; Carissa Bonner; Les Irwig; Jenny Doust; Paul Glasziou; Brooke Nickel; Barbara van Munster; Kirsten McCaffery
Journal:  BMC Fam Pract       Date:  2015-08-20       Impact factor: 2.497

View more
  7 in total

1.  2014 NICE cholesterol guidelines.

Authors:  Andrew Sikorski
Journal:  Br J Gen Pract       Date:  2017-10       Impact factor: 5.386

2.  Statins for primary prevention of cardiovascular disease: modelling guidelines and patient preferences based on an Irish cohort.

Authors:  Paula Byrne; John Cullinan; Paddy Gillespie; Rafael Perera; Susan M Smith
Journal:  Br J Gen Pract       Date:  2019-04-23       Impact factor: 5.386

3.  Prediction of Cardiovascular Disease Risk Accounting for Future Initiation of Statin Treatment.

Authors:  Zhe Xu; Matthew Arnold; David Stevens; Stephen Kaptoge; Lisa Pennells; Michael J Sweeting; Jessica Barrett; Emanuele Di Angelantonio; Angela M Wood
Journal:  Am J Epidemiol       Date:  2021-10-01       Impact factor: 5.363

Review 4.  Statin Therapy in Very Old Patients: Lights and Shadows.

Authors:  Lidia Cobos-Palacios; Jaime Sanz-Cánovas; Mónica Muñoz-Ubeda; María Dolores Lopez-Carmona; Luis Miguel Perez-Belmonte; Almudena Lopez-Sampalo; Ricardo Gomez-Huelgas; Maria Rosa Bernal-Lopez
Journal:  Front Cardiovasc Med       Date:  2021-11-29

5.  The polypharmacy challenge: time for a new script?

Authors:  Deborah Swinglehurst; Nina Fudge
Journal:  Br J Gen Pract       Date:  2017-09       Impact factor: 5.386

6.  Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study.

Authors:  Rafel Ramos; Marc Comas-Cufí; Ruth Martí-Lluch; Elisabeth Balló; Anna Ponjoan; Lia Alves-Cabratosa; Jordi Blanch; Jaume Marrugat; Roberto Elosua; María Grau; Marc Elosua-Bayes; Luis García-Ortiz; Maria Garcia-Gil
Journal:  BMJ       Date:  2018-09-05

7.  Challenges and practical recommendations for successfully recruiting inactive, statin-free older adults to clinical trials.

Authors:  Colleen S Deane; Bethan E Phillips; Kenneth Smith; Anna M Steele; Tina Libretto; Sarah A Statton; Philip J Atherton; Timothy Etheridge
Journal:  BMC Res Notes       Date:  2020-03-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.